ZEBRAFISH AS AN EMERGING MODEL FOR BIOASSAY-GUIDED NATURAL PRODUCT DRUG DISCOVERY FOR NEUROLOGICAL DISORDERS


Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment

Abstract High-dose melphalan at 200 mg/m2 (MEL-200) is the standard conditioning regimen before autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM).Busulfan (BU) and cyclophosphamide (CY) can be used as alternatives when MEL is unavailable.However, most studies on BU/CY conditioning regimens were conducted before prot

read more